Program
Relcobatinib
Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, led by Enliven Therapeutics.
Furthest: phase 3, since Oct 23, 20263 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Enliven Therapeutics | 33 open or running | phase 3since Oct 23, 2026 | Mar 15, 2022 | Dec 2027phase 1 · NCT05304377 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 15, 2022First study: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveFirst studyNCT05304377 · 250 planned · United States, Australia, Belgium and more
- Dec 16, 2024Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06787144 · 21 planned · Japan
- Oct 23, 2026Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositivePhase 3 reachedNCT07905183 · 450 planned
Ahead
- Dec 2027Primary completion: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT05304377
- Jan 2028Primary completion: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06787144
- Dec 31, 2028Primary completion: phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT07905183
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07905183Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | Not yet recruiting | Dec 31, 2028 | 450 |
| NCT06787144Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan | 1 | Recruiting | Jan 2028 | 21 |
| NCT05304377Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Belgium and more | 1 | Recruiting | Dec 2027 | 250 |
How it is read
Names in the registry
- “ELVN-001”, 3 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.